Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | GGT1 | P19440 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876751 | 1.00 | MMP2 (0.73) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL218878 | 1.00 | MMP2 (0.73) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL23051768 | 0.98 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL23051769 | 0.98 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL4343987 | 0.90 | MMP2 (0.60) | MMP2GGT1 | |
| SCHEMBL4343992 | 0.90 | MMP2 (0.60) | MMP2GGT1 | |
| SCHEMBL20717803 | 0.87 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL20717933 | 0.87 | MMP2 (0.71) | MMP2EPHX1ALPIPKMPTGS1 | |
| SCHEMBL20630479 | 0.86 | MMP2 (0.69) | MMP2EPHX1ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL20704629 | 0.86 | MMP2 (0.69) | MMP2EPHX1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3552604-B1 | COMPOSITIONS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK BIOPHARMACEUTICALS CO LTD (KR) | 2020-12-16 | — | — | EP | claimed |
| EP-2445489-B1 | COMPOSITIONS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK BIOPHARMACEUTICALS CO LTD (KR) | 2019-10-30 | — | — | EP | claimed |
| US-20170349541-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-12-07 | — | — | US | claimed |
| US-9610274-B2 | Methods for treating bipolar disorder | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-04-04 | — | — | US | claimed |
| US-20150011625-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-01-08 | — | — | US | claimed |
| US-8927602-B2 | Methods for treating fibromyalgia syndrome | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-01-06 | — | — | US | claimed |
| US-20120252892-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-10-04 | — | — | US | claimed |
| US-20120004301-A1 | METHODS FOR TREATING RESTLESS LEGS SYNDROME | SK HOLDINGS CO., LTD. (KR) | 2012-01-05 | — | — | US | claimed |
| US-20120004300-A1 | METHODS FOR TREATING BIPOLAR DISORDER | SK HOLDINGS CO., LTD. (KR) | 2012-01-05 | — | — | US | claimed |
| EP-2588099-B1 | CARBAMATES FOR USE IN TREATING RESTLESS LEGS SYNDROME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-05-24 | — | — | EP | disclosed |
| US-9649291-B2 | Treatment for obesity | JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED (BM) | 2017-05-16 | — | — | US | disclosed |
| US-9604917-B2 | Treatment of sleep-wake disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-28 | — | — | US | disclosed |
| US-9464041-B2 | Methods for treating or preventing fatigue | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-10-11 | — | — | US | disclosed |
| US-9359290-B2 | Treatment of cataplexy | JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED (BM) | 2016-06-07 | — | — | US | disclosed |
| US-20140275244-A1 | Treatment of Cataplexy | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140243406-A1 | Methods for Treating or Preventing Fatigue | SK Biopharmaceuticals, Co., Ltd. (KR) | 2014-08-28 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2002836-B1 | Cyclocondensed azaindoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-10-20 | — | — | EP | disclosed |
| EP-2070928-A1 | 7-azaindol-3-ylacrylamides active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-06-17 | — | — | EP | disclosed |
| EP-2002836-A1 | Cyclocondensed azaindoles active as kinase inhibitors | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349541-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | FAAH, NEFM, CPT1B | MMP2 1697/4885EPHX1 4012/4885ALPI 3635/4885 |
| US-20120004301-A1 | METHODS FOR TREATING RESTLESS LEGS SYNDROME | HCRTR2, HCRTR1, CHAT | MMP2 4170/4885EPHX1 3683/4885ALPI 1397/4885 |
| US-20140243406-A1 | Methods for Treating or Preventing Fatigue | GSTO1, GSTA2, CPT1B | MMP2 1591/4885EPHX1 1266/4885ALPI 684/4885 |
| US-20120252892-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | FAAH, NEFM, CPT1B | MMP2 1697/4885EPHX1 4012/4885ALPI 3635/4885 |
| US-20140275244-A1 | Treatment of Cataplexy | CHAT, HCRTR1, HCRTR2 | MMP2 2017/4885EPHX1 1269/4885ALPI 3983/4885 |
| US-20150011625-A1 | METHODS FOR TREATING FIBROMYALGIA SYNDROME | FAAH, NEFM, CPT1B | MMP2 1697/4885EPHX1 4012/4885ALPI 3635/4885 |
| US-20120004300-A1 | METHODS FOR TREATING BIPOLAR DISORDER | GABBR2, GABBR1, HDAC3 | MMP2 1959/4885EPHX1 3451/4885ALPI 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.